Adaptimmune Therapeutics Plc Return on Equity

Adaptimmune Therapeutics Plc (ADAP) currently reports a ROE of 239.23%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Adaptimmune Therapeutics Plc's ROE history and peer comparisons.

Adaptimmune Therapeutics Plc's ROE of 239.23% is higher than the Healthcare sector average of 21.67%. That is roughly 1004.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adaptimmune Therapeutics Plc's current 239.23% should be judged against Healthcare norms (sector average: 21.67%) and against ADAP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 239.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.

Adaptimmune Therapeutics Plc is classified in the Healthcare sector. On ROE, it currently shows 239.23% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADAP with unrelated industries.